Kontigo Care (KONT) Q3 2025 earnings summary

Executive summary

• MRR at quarter-end was 2.39 MSEK, up 0.9% sequentially but down 3.2% year-over-year.

• Net sales for Q3 were 7.4 MSEK, a 2.1% decrease year-over-year, with EBIT of 1.0 MSEK and a margin of 14.0%.

• New product strategy and website launched, shifting focus from research to product company.

• Five of six public tenders won, increasing potential order value by over 10 MSEK.

• Fourth scientific article published, validating smartphone-based opioid detection.

Financial highlights

• Q3 net sales: 7.4 MSEK (down 2.1% YoY); 9-month net sales: 21.6 MSEK (down 5.0% YoY).

• Q3 EBIT: 1.0 MSEK (margin 14.0%); 9-month EBIT: -0.9 MSEK (margin -4.1%).

• Q3 net income: 1.1 MSEK (EPS 0.03 SEK); 9-month net loss: -0.8 MSEK (EPS -0.02 SEK).

• Q3 gross margin: 88.1% (up from 86.4% YoY).

• Free cash flow for Q3: 0.1 MSEK; 9-month free cash flow: -4.3 MSEK.

Outlook and guidance

• No formal forecasts provided; management notes longer sales cycles and continued macroeconomic challenges.

• Focus remains on expanding customer base, product scalability, and recurring revenue.